OTCMKTS:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis → Tiny, One-Half Inch Pellet the Key to INFINITE Energy? (From Eagle Publishing) (Ad) Free PPCB Stock Alerts $0.0021 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.0019▼$0.002950-Day Range N/A52-Week Range$0.00▼$0.26Volume54.39 million shsAverage Volume39.40 million shsMarket Capitalization$352,758.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Propanc Biopharma alerts: Email Address Ad Eagle PublishingTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its kind in the U.S. It’s in a prime position to profit.For the full story, click here About Propanc Biopharma Stock (OTCMKTS:PPCB)Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Read More PPCB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPCB Stock News HeadlinesMay 29, 2024 | seekingalpha.comVTXB Vortex Brands Co.May 29, 2024 | finance.yahoo.comPropanc Biopharma, Inc. (PPCB)April 16, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 10, 2024 | stockhouse.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingFebruary 22, 2024 | finance.yahoo.comPropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use StudyJanuary 16, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property OfficeDecember 18, 2023 | finance.yahoo.comPropanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment OpportunitiesDecember 13, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRPDecember 12, 2023 | finance.yahoo.comJames Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDailyNovember 7, 2023 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsAugust 15, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaJuly 26, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030July 13, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 5, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJune 30, 2023 | sg.finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 28, 2023 | finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeMay 23, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 16, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 14, 2023 | benzinga.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, PredictionsFebruary 23, 2023 | seekingalpha.comPPCB Propanc Biopharma, Inc.See More Headlines Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PPCB CUSIPN/A CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,660,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,700.65% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book0.00Miscellaneous Outstanding Shares167,980,000Free Float164,955,000Market Cap$352,758.00 OptionableNot Optionable Beta2.25 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. James Nathanielsz (Age 50)Executive Chairman, CEO, CFO, Treasurer & Secretary Comp: $430.28kDr. Julian Norman Kenyon ChB (Age 76)M.D., MB, Chief Scientific Officer, CTO & Director Comp: $35.99kProf. Klaus KutzChief Medical Officer & Member of Scientific Advisory BoardKey CompetitorsVirpax PharmaceuticalsNASDAQ:VRPXCNS PharmaceuticalsNASDAQ:CNSPBellerophon TherapeuticsNASDAQ:BLPHHistogenNASDAQ:HSTOComera Life SciencesNASDAQ:CMRAView All Competitors PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed in 2024? Propanc Biopharma's stock was trading at $0.0120 at the beginning of the year. Since then, PPCB stock has decreased by 82.5% and is now trading at $0.0021. View the best growth stocks for 2024 here. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma, Inc. (OTCMKTS:PPCB) posted its earnings results on Wednesday, May, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. When did Propanc Biopharma's stock split? Shares of Propanc Biopharma reverse split on the morning of Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF). How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PPCB) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.